$23.72
0.25% yesterday
Nasdaq, Nov 12, 10:00 pm CET
ISIN
US91678A1079
Symbol
UPB

Upstream Bio Stock price

$23.72
+3.64 18.13% 1M
+14.22 149.68% 6M
+7.28 44.28% YTD
-2.66 10.08% 1Y
+6.72 39.53% 3Y
+6.72 39.53% 5Y
+6.72 39.53% 10Y
+6.72 39.53% 20Y
Nasdaq, Closing price Wed, Nov 12 2025
-0.06 0.25%
ISIN
US91678A1079
Symbol
UPB
Industry

Key metrics

Basic
Market capitalization
$1.3b
Enterprise Value
$912.6m
Net debt
positive
Cash
$372.4m
Shares outstanding
54.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
458.9 | 520.7
EV/Sales
325.9 | 369.8
EV/FCF
negative
P/B
3.4
Financial Health
Equity Ratio
97.5%
Return on Equity
-16.3%
ROCE
-37.1%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$2.8m | $2.5m
EBITDA
$-140.3m | $-160.6m
EBIT
$-140.5m | $-166.6m
Net Income
$-122.8m | $-154.0m
Free Cash Flow
$-122.6m
Growth (TTM | estimate)
Revenue
26.7% | 4.1%
EBITDA
-113.6% | -106.7%
EBIT
-113.6% | -114.3%
Net Income
-76.4% | -101.6%
Free Cash Flow
-101.5%
Margin (TTM | estimate)
Gross
-
EBITDA
-5,013.7% | -6,506.9%
EBIT
-5,020.1%
Net
-4,386.4% | -6,240.7%
Free Cash Flow
-4,378.4%
More
EPS
$-2.3
FCF per Share
$-2.3
Short interest
11.2%
Employees
-
Rev per Employee
-
Show more

Is Upstream Bio a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,031 stocks worldwide.

Upstream Bio Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Upstream Bio forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Upstream Bio forecast:

Buy
89%
Hold
11%

Financial data from Upstream Bio

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
2.80 2.80
27% 27%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 25 25
46% 46%
889%
- Research and Development Expense 118 118
124% 124%
4,229%
-140 -140
114% 114%
-5,012%
- Depreciation and Amortization 0.18 0.18
157% 157%
6%
EBIT (Operating Income) EBIT -141 -141
114% 114%
-5,018%
Net Profit -123 -123
76% 76%
-4,385%

In millions USD.

Don't miss a Thing! We will send you all news about Upstream Bio directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Upstream Bio Stock News

Neutral
GlobeNewsWire
7 days ago
– Positive top-line results from VIBRANT Phase 2 trial of verekitug in CRSwNP reported in September showed statistically significant and clinically meaningful effects on primary and key secondary endpoints when administered once every 12 weeks –
Neutral
GlobeNewsWire
13 days ago
WALTHAM, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will be participating in the following upcoming investor conferences in November:
Neutral
GlobeNewsWire
about one month ago
– Data show verekitug prevents TSLP binding to the TSLP receptor by occupying ligand binding sites – – Additionally, findings show that verekitug outcompetes TSLP in the presence of preformed heterodimeric receptor complexes – – Data support the potential of verekitug's unique mechanism of action to achieve a differentiated therapeutic effect across a broad range of TSLP-driven severe respirato...
More Upstream Bio News

Company Profile

Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It develops verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin. The company was founded in April 2021 and is headquartered in Waltham, MA.

Head office United States
CEO E. Sutherland
Website upstreambio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today